Profile:SciClone Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics to treat life-threatening diseases. The company in-licenses products in the areas of cancer and viral infectious diseases, and develops them for commercialization in the various pharmaceutical markets with a particular focus on China. It sells ZADAXIN (thymalfasin) in China for liver disease, cancer, and the intensive care. ZADAXIN is in late-stage clinical development in Europe for the treatment of malignant melanoma and hepatitis C virus. The company's other product candidates include proprietary in-licensed compound SCV-07, an orally available immune system modulator known to act on the TLR pathway, which has completed phase 1 clinical trial for viral infectious disease; and RP101, a clinical-stage drug development candidate for the treatment of pancreatic cancer. SciClone Pharmaceuticals also holds Chinese marketing rights, from Biocompatibles International plc., for the DC Bead embolizing and chemotherapy releasing device. The company was founded in 1989 and is headquartered in San Mateo, California.
|aus der Diskussion:||SciClone Pharmaceuticals, Inc. (SCLN)|
|Autor (Datum des Eintrages):||panik (27.07.07 15:40:18)|
|Beitrag:||1 von 3 (ID:30877851)|
|Alle Angaben ohne Gewähr © wallstreet:online|